Starting Mounjaro at 5mg — is it the right call for you?

Why the standard first pen is 2.5mg, and what that means for skipping it

The Mounjaro prescribing schedule is built around a simple idea: give your body time to adjust before asking it to do more. The 2.5mg pen exists specifically to reduce the GI effects that hit hardest in the first weeks of treatment (nausea, stomach cramps, loose stools) so that when you step up to 5mg after roughly four weeks, the transition is far smoother than it would have been from zero.

That's not a conservative guess; it's the pattern that emerged across the SURMOUNT clinical programme, which the NHS tirzepatide medicines page reflects in its guidance. When people begin on 5mg having never taken tirzepatide, the GI burden is noticeably heavier. For some, that's manageable. For others, it's the reason they stop treatment early, which means missing out on the weight loss they set out to achieve.

None of this makes 5mg the wrong answer for everyone. It makes it the wrong default for people who have no prior exposure to the medicine. If your question is whether starting on 5mg Mounjaro is ever appropriate, the answer is yes, but the conditions that make it appropriate are specific, and a prescriber has to assess them.

A useful comparison of the two entry points is covered in our page on Mounjaro 2.5mg versus 5mg, if you're weighing the trade-offs before your consultation.

Who a prescriber might consider for a 5mg start

There are two main groups for whom starting on 5mg Mounjaro becomes a realistic clinical conversation.

The first is transfer patients. If you've been on tirzepatide at 5mg for at least four weeks at another service, have tolerated it well and have documented evidence of that (a letter from your previous prescriber, a prescription record, clinical notes) a reviewing prescriber may agree to continue at 5mg rather than restart from 2.5mg. The evidence requirement matters. Dose increases and transfers carry a higher clinical risk than straightforward repeats, which is why regulated services ask for it. What this looks like in practice at a GPhC-registered pharmacy is outlined on our Mounjaro 5mg page.

The second group is smaller: people with a documented history of GLP-1 use (for example, semaglutide via Wegovy) who have already demonstrated good tolerance of this class of medicine and whose prescriber judges that the 2.5mg phase adds little practical value. This is uncommon and not a standard pathway; it's a clinical judgement call, not something you can self-select into.

Worth noting: whether you can start Mounjaro at 5mg is genuinely one of the more frequent questions our prescribers field. The answer is almost always the same, it depends on what happened before you arrived.

What the side-effect picture looks like at 5mg from the start

If you do begin at 5mg, knowing what to watch for matters. The side-effect profile of tirzepatide is broadly GI-led: nausea is the most common, followed by loose stools, vomiting, constipation, reflux and fatigue. These tend to peak in the first one to two weeks after a new or increased dose and then ease off as your body adjusts.

At 5mg as a first dose (rather than as a step up from 2.5mg) those effects tend to arrive with more intensity. Most people find them manageable with practical adjustments: smaller meals, eating slowly, keeping well hydrated, avoiding high-fat or very spicy food while your system settles. Some people keep their pen in the fridge door and find that injecting on a Saturday morning, with a quieter day ahead, helps them get through the first few days of each new dose more comfortably.

The NICE appraisal of tirzepatide, TA1026, notes that tolerability is a key consideration in dose progression, which is exactly why the schedule is designed the way it is. Missed doses, questions about timing, and any concerns about side effects should go to your prescriber or the Patient Information Leaflet, not be managed independently.

One situation that always warrants urgent attention: severe, persistent stomach pain that radiates toward the back, with or without vomiting, can be a sign of pancreatitis. Seek medical help promptly if that happens, it is uncommon, but the MHRA has highlighted it as a known risk for this class of medicine.

What to expect from a clinical review before any dose is confirmed

Understanding the process helps, especially if you've been through a less thorough service before. A prescriber reviewing a request to start on 5mg Mounjaro will typically want to know your weight and BMI, any relevant medical history, your current medications, and (for transfers) evidence of your previous dose and how you tolerated it. That review happens before any prescription is issued, not as a formality after.

This is the point at which your eligibility is assessed: the licensed threshold for Mounjaro in the UK is a BMI of 30 or above, or 27 or above if you have a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Full eligibility detail, including how the Mounjaro starting dose is determined for different patients, is on our Mounjaro starting dose for weight loss page.

If you're exploring what the process looks like end to end, our Mounjaro overview covers the full clinical and practical picture. And if you're ready to have the dose question answered for your specific situation, speak to our prescribers, a GPhC-registered clinician, not a piece of software, will read your consultation the same day.